Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
INTRODUCTION — The first description of acute HIV infection, a "mononucleosis-like" illness, based upon the clinical records of 12 men with documented seroconversion to HIV during the preceding six months, was published in 1985 . Since then, the early period following acquisition of HIV has been a subject of tremendous clinical and research interest, yet many challenges remain in its diagnosis, management, and impact on public health.
Difficulties in identifying patients with early HIV infection have hindered the performance of trials to evaluate the long-term clinical benefits of initiation of antiretroviral therapy during this stage of infection. Thus, decisions for treatment initiation during this period must balance the potential benefits based on indirect evidence, including effects on surrogate markers, and the potential risks of earlier therapy. In addition, the general trend in treatment guidelines in favor of treating all individuals with HIV infection influences the approach in early infection toward treatment .
The treatment of early HIV infection will be reviewed here. The pathogenesis, epidemiology, clinical manifestations, and diagnosis of acute and early infection with HIV are discussed separately. (See "Acute and early HIV infection: Pathogenesis and epidemiology" and "Acute and early HIV infection: Clinical manifestations and diagnosis".)
DEFINITIONS — Different terms, including acute, recent, primary, and early HIV infection, have been used in the literature to refer to variable intervals following initial infection with the virus. In this topic, we use the term "early HIV infection" to refer to the approximate six-month period following HIV acquisition. We use the term "acute HIV infection," to refer to symptomatic early infection, as this reflects common usage in clinical care.
DECISION TO INITIATE ANTIRETROVIRAL THERAPY DURING EARLY HIV INFECTION — For chronically infected HIV patients, a growing body of evidence from trials and large observational studies that demonstrate a reduction in AIDS and non-AIDS morbidity and mortality with antiretroviral therapy (ART) across a wide range of CD4 cell counts has led to the recommendation by many experts for ART initiation regardless of CD4 cell count. (See "When to initiate antiretroviral therapy in HIV-infected patients", section on 'Benefits of antiretroviral therapy'.)
However, because of difficulties in identifying patients with early infection, there are fewer clear data on the clinical long-term benefits of initiating treatment during this stage of HIV infection. Thus, most of the rationale for initiating treatment in early HIV infection is extrapolated from indirect evidence, theoretical benefits, and effects of ART on surrogate markers of HIV disease progression (ie, CD4 cell count and HIV RNA). The decision to initiate antiretroviral therapy in early infection must balance these potential benefits with the potential risks of ART.
Rationale for initiation of ART in early infection
Effect on symptomatic disease — The presence and severity of symptoms during early HIV infection appear to portend more rapid disease progression [3-5]. As an example, in a study of 218 female sex workers with well-documented dates of HIV seroconversion based on longitudinal screening, in the absence of HIV treatment, each additional symptom present at the time of acute infection was associated with an increasing risk of overall mortality after a median follow-up of 4.6 years . Thus, those with acute symptomatic HIV infection may represent a subset of patients in whom earlier initiation of ART would be more likely to confer improvement in morbidity and mortality that would thus outweigh potential risks.
Additionally, because symptoms of acute HIV infection are thought to be related to the high level of circulating virus, either through direct effect or indirectly through the immune response to viral infection, early treatment with ART, through rapid reduction in the HIV RNA level, may be able to attenuate the severity of symptoms. However, there are no clinical data that clearly demonstrate this theoretical effect.
Improved clinical markers of disease — As in chronic infection, ART is effective in suppressing serum viral RNA levels and increasing CD4 cell counts in the vast majority of patients with acute and early HIV infection. As an example, in a prospective longitudinal study of 102 patients infected with HIV within the preceding 12 months who initiated ART, 97 percent achieved undetectable viral levels at a median of 11 weeks, and 66 of 72 patients (92 percent) maintained virologic suppression at 18 months . The CD4 cell count increased from a mean nadir of 422 cells/mm3 to a mean of 702 cells/mm3.
Furthermore, initiation of ART earlier after initial HIV infection is associated with a greater chance of immune reconstitution to normal or near normal CD4 cell levels. In a prospective study of predominantly white men with a well-estimated date of HIV infection, a peak in the CD4 cell count at four months after infection followed by a progressive decline was observed in the absence of ART . Among the 97 patients who initiated ART within that four-month window, the likelihood and rate of CD4 cell count recovery were both greater compared with the 116 patients who initiated ART at a later time (64 versus 34 percent achieved a CD4 cell count >900 cells/mm3 by 48 months of ART and at a median of 3.8 versus 15.2 months after ART initiation, respectively). CD4 cell count recovery to this threshold was also more likely and rapid in patients who initiated therapy at a baseline CD4 cell count greater than 500 cells/mm3 versus less than 500 cells/mm3. Although patients treated within four months of infection had higher average CD4 cell counts at initiation than those treated later, in multivariate analyses, initiation of ART earlier and at a higher CD4 cell count each remained independent predictors of CD4 cell count recovery.
Limitations of this observational study include heterogeneity between the two groups (ie, there were a greater number of non-white patients in the group who initiated ART later), the possibility that those treated earlier may have had other unspecified clinical characteristics that would have impacted CD4 cell count recovery, and the lack of clinical end-points. Nevertheless, the results support the concept that earlier treatment following HIV acquisition is associated with improvements in an important surrogate marker of HIV disease.
Interval until treatment criteria are met is short — With mounting data demonstrating benefits of ART for chronically infected HIV patients at increasingly higher CD4 cell counts, the interval following initial infection until the CD4 cell count declines to a threshold at which there is clinical evidence for a benefit with ART is likewise relatively short. Data from observational studies and a controlled trial suggest that initiation of ART in chronically infected patients with CD4 cell counts between 350 and 500 cells/mm3 decreases AIDS-related events and improves survival [8-12]. There are fewer data for the benefit of ART initiation in patients with CD4 cell counts greater than 500 cells/mm3, but results of a large observational study suggest a decreased risk of death with treatment above that CD4 cell count threshold . These data are discussed in greater detail elsewhere. (See "When to initiate antiretroviral therapy in HIV-infected patients", section on 'Benefits of antiretroviral therapy'.)
The time to reach these CD4 cell count levels following HIV acquisition appears relatively short. In one study of patients acutely infected with HIV, the probability of having a CD4 cell count less than 500 cells/mm3 was 0.57, 0.72, 0.79 and 0.84 at baseline, two, four, and six years . Similarly, in a large prospective study of patients with well-estimated dates of HIV infection (the Concerted Action on Seroconversion to AIDS and Death in Europe, or CASCADE cohort), the estimated median time from infection to CD4 cell count decline to <500 cells/mm3 was 1.19 years . Even if lower CD4 cell count thresholds are used, the time to meeting them may also be relatively short. As an example, one trial evaluating treatment of patients with early HIV infection was halted prematurely because a considerable proportion of the 40 patients randomly assigned to delay ART required ART initiation within the trial period; specifically, 28 and 50 percent at 36 and 72 weeks, respectively, reached a CD4 cell count <350 cells/mm3 .
Thus, patients with early HIV who start therapy would likely not have a significant excess of ART exposure compared with deferring therapy until CD4 cell counts decline to a level at which ART has been demonstrated to provide clinical benefit. A limitation to these data is that they largely focus on individuals who are diagnosed with early HIV infection after presenting with acute symptoms and thus focus on a population likely to have a more rapid CD4 decline.
Decreased risk of transmission — Early HIV infection is associated with high levels of HIV RNA and a corresponding high risk of viral transmission [16,17]. Although the estimated contribution of early HIV infection to new infections within a community differs by population studied and model used, in some cases, up to 50 percent of new infections are thought to be transmitted from acutely infected individuals [16,18-23]. (See "Acute and early HIV infection: Pathogenesis and epidemiology", section on 'Infectivity'.)
No clinical trials have directly assessed the effect of treatment of early HIV infection on subsequent transmission rates. However, data from studies of chronically infected patients demonstrates that reduction of viral load through effective ART substantially reduces transmission to uninfected sexual partners  (see "HIV infection: Risk factors and prevention strategies"). It is reasonable to assume that a reduction in transmission risk would similarly occur with lowering and suppressing viral RNA level through ART in patients with early HIV infection.
Decreased viral reservoir and improved markers of immune cell function — Several studies have suggested that ART initiated early during HIV infection can lead to improvements in the ability of immune cells to control the virus and limit the size of the cellular viral reservoir, which contributes to the persistence of infection despite active ART [24-30]. In a study of young men who have sex with men (MSM) diagnosed with early HIV infection, levels of CD4 and CD8 cell activation (which are associated with chronic inflammation) decreased to a greater extent following ART initiation among 34 patients who initiated ART early compared with 32 patients who waited at least two years to initiate ART . Early ART was also associated with lower HIV DNA and RNA cellular reservoir sizes. Even among those treated during early infection, the effect on HIV viral reservoirs may be greatest among those treated the earliest. In a study of 68 patients who were initiated on ART during very early HIV infection (prior to the development of a positive Western Blot), the quantity of HIV DNA integrated into long lasting peripheral blood mononuclear cells, and central memory CD4 cells was lowest at the time of diagnosis among those diagnosed the earliest after infection (prior to the development of detectable HIV antigen and reactive HIV antibody) . After 24 weeks of ART, nearly all participants had undetectable levels of HIV DNA in peripheral blood mononuclear cells. Other studies have suggested that ART in early infection leads to more rapid declines in cellular viral reservoirs compared with treatment in chronic infection [24,25,29].
Furthermore, there is evidence that the effect of early ART on the latent reservoir occurs early and increases over time. As an example, in a study of 80 individuals with early HIV infection, initiation of early ART (mostly within the first two weeks of infection) was associated with total HIV DNA levels that were 20-fold lower at two weeks following initiation than in those who had no ART and over 300-fold lower levels three years later .
In addition, initiation of ART during acute infection appears to preserve HIV-specific T cell function that would otherwise deteriorate [32,33]. Markers of B cell dysfunction and apoptosis that are seen in chronic infection appear during early HIV infection and can also be reversed with early ART initiation .
Whether restriction of the viral reservoir and changes in markers of immune function or activation translate into clinical benefits is as yet unclear. Nevertheless, these observations have continued to fuel interest in to potential of early ART to alter the natural history of HIV disease such that ART may not have to be continued indefinitely or other cure strategies may be more effective. Studies evaluating this theory are discussed in detail below. Of note, treatment interruption strategies are not recommended at any stage of HIV infection; hence these studies are summarized primarily because of the lessons learned about this distinctive population with recently acquired HIV. (See 'Can ART in early infection alter disease course?' below.)
Potential risks — The potential benefits of early treatment must be balanced against the possible risks of ART.
One concern for initiating ART during early infection, when the rate of viral replication is particularly rapid, is that suboptimal adherence could more readily lead to the evolution of drug resistance mutations. However, there is no clinical evidence that resistance is more likely to occur in patients treated during early HIV infection than with long-established disease. Nevertheless, commitment to strict adherence if treatment is initiated at this time is important.
Additionally, although current antiretroviral options have more favorable side effect profiles than their predecessors, concerns about toxicities with the long-term use of ART remain, including the metabolic risks of protease inhibitors and the effect of tenofovir on bone density and renal function. However, whether delaying ART until criteria for treatment in chronic infection are met would attenuate these risks is unknown. Furthermore, the current trend towards initiating ART at higher CD4 cell counts minimizes the amount of ART exposure that a patient would be spared by deferring treatment until those criteria are met, as above. (See 'Interval until treatment criteria are met is short' above.)
Recommendations from expert groups — In the United States, the Department of Health and Human Services (DHHS) guidelines on the treatment of HIV recommend initiation of ART for all HIV-infected patients, including those with early HIV infection . Initiation of ART is specifically recommended for pregnant women with early HIV infection, in order to reduce the risk of transmission to the infant. (See "Antiretroviral and intrapartum management of pregnant HIV-infected women and their infants in resource-rich settings".)
Treatment guidelines from the International-AIDS Society-USA recommend ART for patients with acute symptomatic HIV infection to prevent rapid progression and preserve immune function . Although these guidelines acknowledge the potential benefits for initiating ART in the setting of early HIV and note that offering treatment to acutely infected patients is a high priority for prevention strategies, they do not specifically make recommendations for ART in asymptomatic patients with early HIV infection.
Our approach — As with patients with established HIV, we recommend that all patients with acute or early HIV infection initiate antiretroviral therapy because the potential benefits to the individual and to public health outweigh the possible drawbacks of earlier ART. Those with acute symptomatic infection, in particular, may be at greatest risk of delaying therapy given the association between symptomatic disease and more rapid progression, and our recommendation to start therapy is thus stronger for this group.
Since there is no controlled clinical trial comparing immediate versus deferred continual therapy in patients with early HIV, for individuals who are not committed to taking therapy or who have significant barriers to adherence, a strategy of monitoring without HIV treatment is reasonable.
MANAGEMENT OF EARLY HIV INFECTION
Patients who initiate antiretroviral therapy
Treatment setting — After a diagnosis of acute or early HIV infection is made, patients should ideally be referred to a provider with experience in HIV management. We also offer all patients with early HIV the opportunity to participate in clinical studies exploring the pathogenesis of HIV disease and its immunologic response. Listings of available trials can be found at www.clinicaltrials.gov.
Selection of antiretroviral regimen — If the decision is made to treat a patient with acute or early HIV infection, the ultimate choice of antiretroviral regimen should be guided by the results of drug resistance testing, as transmission of virus harboring at least one resistance mutation has been reported in up to 20 percent of patients with early HIV infection [36-38]. (See "Acute and early HIV infection: Clinical manifestations and diagnosis" and "Drug resistance testing in the clinical management of HIV infection", section on 'Interpretation of resistance testing'.)
However, once the decision is made to treat a patient with early HIV infection, we initiate treatment as soon as feasible, even if this is before results of baseline resistance testing are known. In such cases, a regimen that contains a boosted protease inhibitor (ie, ritonavir boosted darunavir with tenofovir-emtricitabine) may be preferable to a regimen that contains a non-nucleoside reverse transcriptase inhibitor, as clinically significant transmitted resistance to the former is uncommon . In a study of 109 patients with primary HIV infection, the 13 patients infected with virus that harbored minority variant resistance mutations (including the M184V mutation that confers resistance to lamivudine and emtricitabine) all achieved virological suppression on a protease inhibitor-based regimen . Since transmission of virus resistant to HIV integrase inhibitors is also uncommon, some clinicians may elect to use a drug from this class in place of the ritonavir-boosted protease inhibitor.
Once the results of resistance testing are available, treatment modifications can be made accordingly.
In the event that a patient is infected with wild-type virus, we agree with the United States Department of Health and Human Services recommendations to initiate one of the first-line regimens recommended for chronic HIV infection . Data comparing the efficacy of various antiretroviral (ART) regimens in patients with early HIV infection are limited . (See "Selecting antiretroviral regimens for the treatment-naïve HIV-infected patient".)
There does not appear to be a benefit to using intensified regimens in early or acute HIV infection. In one study of 92 patients with symptomatic acute HIV infection randomly assigned to a three- or five-antiretroviral drug regimen, there were no differences in HIV DNA levels in peripheral blood mononuclear cells (thought to reflect the blood reservoir), rates of viral suppression, or increases in CD4 cell counts between the groups at 24 months .
Monitoring during antiretroviral therapy — Following initiation of ART during early HIV infection, viral RNA levels should be checked regularly to document and ensure viral suppression. This can be done at intervals recommended for patients starting ART during chronic infection, as time to viral suppression on ART is comparable in early and chronic infection . (See "Patient monitoring during HIV antiretroviral therapy", section on 'Frequency of immunologic and virologic monitoring'.)
Routine monitoring of other laboratory tests and for side effects is also similar to that recommended for chronic infection. (See "Patient monitoring during HIV antiretroviral therapy", section on 'Frequency of immunologic and virologic monitoring'.)
Duration of treatment — Once treatment is initiated, ART is continued indefinitely.
Although many studies have attempted to evaluate the benefit of a discrete course of ART initiated during acute or early infection followed by treatment interruption, results from these studies have been mixed and there is no clear evidence of long-term benefit of such an approach (see 'Can ART in early infection alter disease course?' below). In contrast, controlled trials have demonstrated that treatment interruption following initiation of ART during chronic infection is strongly associated with an increase in mortality as well as AIDS and non-AIDS morbidity [42,43]; thus treatment interruption is not a recommended strategy.
Although the rebound in viral load following treatment interruption may be lower among those who initiated ART during early compared with chronic infection , there is no evidence that treatment interruptions are safer in this setting
Patients who defer antiretroviral therapy — Although we generally favor earlier initiation of ART for patients with early HIV infection, some patients will opt to defer ART or otherwise not be ready to commit to lifelong ART. If a decision is made to defer therapy, we perform close clinical and laboratory (CD4 cell count and viral load testing) monitoring (ie, every three months) for evidence of rapid immunologic decline, which would indicate a greater urgency for initiation of ART to prevent poor clinical outcomes. Additionally, patients should be counseled on the high risk of transmission in the setting of primary HIV infection, when viral RNA levels are typically very high.
CAN ART IN EARLY INFECTION ALTER DISEASE COURSE? — There has long been interest in whether a discrete course of antiretroviral therapy (ART) started in the earliest stages of infection could alter the natural progression of the disease, decreasing the viral load set point, increasing the time to CD4 cell count decline, and thus delaying the time to reinitiate ART for clinical indications. Studies that demonstrate very low viral reservoirs in patients who are treated at the earliest periods after infection have raised the possibility that early ART could induce a "functional cure" or even prevent establishment of a latent reservoir [26,27,45].
In one case report, an individual participating in an HIV pre-exposure prophylaxis (PrEP) study was confirmed HIV-uninfected by pooled RNA, fourth generation enzyme immunoassay (EIA), and rapid antibody testing at two pre-study visits . However, seven days after PrEP with tenofovir-emtricitabine was initiated, baseline testing results returned, demonstrating an HIV RNA of 220 copies/mL and negative 4th generation EIA and rapid antibody testing, indicating Fiebig stage 1 infection. He was then switched to suppressive ART. Approximately one month after infection, he had a single measurement of cell-associated HIV RNA at a level of 4.7 copies per million CD4 cells, but all subsequent tests for HIV RNA, DNA, and replication-competent virus were negative. Importantly, the patient remained on ART. These results raise the possibility that full seeding of the viral reservoir was prevented by this very early treatment.
Additionally, reports of individuals who have experienced a persistent control of viral replication after a discrete course of ART during early infection have continued to suggest the potential of a functional cure following early treatment [47,48]. As an example, the Visconti cohort consists of 14 individuals who achieved prolonged (median 89 months) viral suppression after an approximate three year course of ART initiated within ten weeks of presentation of acute HIV infection . These individuals had genetic backgrounds and initial presentations distinct from those individuals who are able to spontaneously control HIV (ie, elite controllers), yet maintained similarly low levels of HIV DNA in peripheral blood mononuclear cells after ART discontinuation. Likewise, in a highly publicized case, an infant diagnosed with HIV infection and initiated on ART within 30 hours of birth maintained an undetectable HIV viral load two years after discontinuing treatment at 18 months of age . However, in a disappointing development, the child was subsequently found to have detectable virus and decline in the CD4 cell count on routine follow-up at age four, prompting reinitiation of ART .
It has been difficult to identify and enroll patients in studies to evaluate the hypothesis that a short course of ART can alter HIV natural history, and results from the few controlled trials that have been performed are mixed [15,50-52]. Even in those trials that demonstrate a benefit to short-term ART in the acute setting with regards to HIV disease parameters, the duration and clinical significance of these benefits are unclear. Results from other observational studies are similarly inconsistent [53-58]. Given the substantial evidence from clinical trials of poor clinical outcomes associated with treatment interruption in the setting of chronic HIV infection, we do not recommend a temporary course of early ART for acutely infected patients [42,43].
The range of findings from trials evaluating the effects of short-term ART in the setting of early HIV infection is illustrated as follows:
●In an open-label trial (Primo-SHM) of 115 patients with HIV seroconversion within the preceding six months, patients randomly assigned to receive an early, discrete course of ART experienced modest improvements in clinical markers of disease following treatment interruption compared with patients whose ART was delayed until clinically indicated .
●Similar findings were reported from an international trial (Short Pulse Anti-Retroviral Therapy at Seroconversion, or SPARTAC) of 366 patients with HIV seroconversion within the preceding six months who were randomly assigned to receive 12 weeks of ART, 48 weeks of ART, or no ART . The primary endpoint was a CD4 cell count decline <350 cells/mm3 or other indication for long-term ART initiation, and patients were followed for a mean of 4.2 years. Patients who received an early, temporary ART regimen for 48 weeks had a longer time following treatment interruption to reach the primary endpoint (median 222 weeks) compared with those who received 12 weeks of ART (median 184 weeks) and those who did not receive ART in the setting of early infection (median 157 weeks following randomization to meeting criteria for long-term ART). In a post-hoc analysis, there was a nonsignificant trend towards a longer time to CD4 cell count decline among patients who initiated the 48-week ART course earlier following seroconversion. Additionally, the mean decrease in viral RNA level from baseline was greater in patients who received 48 weeks of ART compared with those who received no ART when measured at 36 weeks following treatment interruption or randomization, respectively (difference -0.44 log copies/mL). There were no differences between the three groups in AIDS diagnoses or death within the limited follow-up period.
●In a separate trial (AIDS Clinical Trial Group A5217), 130 patients who were infected with HIV within the preceding six months but had already developed a positive Western blot were randomly assigned to receive 36 weeks of immediate ART followed by treatment discontinuation or to delay ART until prespecified treatment criteria were met (including CD4 cell count <350 cells/mm3 consecutively over at least four weeks or <200 cells/mm3 at any time) . The primary objective of the trial was to assess the effect of early ART on viral RNA levels once off treatment. However, the study was discontinued prematurely because of a high rate of progression to treatment requirement in the delayed ART arm.
The aggregate message from these controlled trials is that a course of early therapy does provide some benefits in surrogate markers of HIV disease (ie, the CD4 cell count and HIV RNA). However, since treatment interruption is not a recommended strategy in HIV disease management, the practical importance of the particular strategies evaluated in these studies for clinical management is presently limited. They are summarized here primarily because of the lessons learned about this distinctive population with recently acquired HIV. Nevertheless, the greater likelihood of CD4 preservation , the possibility of an alteration in disease course, the potential implications for future cure strategies, and the reduction in HIV transmission risk on balance support initiation of ART during acute or early HIV infection. Based on this information, some HIV treatment guidelines endorse this strategy [2,35]. (See 'Rationale for initiation of ART in early infection' above.)
SUMMARY AND RECOMMENDATIONS
●In this topic, we use the term "early HIV infection" to refer to the approximate six-month period following HIV acquisition. We use the term "acute HIV infection," to refer to symptomatic early infection. (See 'Definitions' above.)
●Because of difficulties in identifying patients with early HIV infection for enrollment in controlled trials, most of the rationale for initiating antiretroviral treatment (ART) in early HIV infection is based on indirect evidence from chronic infection, theoretical benefits to the individual and public health, and the effects of ART during early infection on surrogate markers of HIV disease progression (ie, CD4 cell count and HIV RNA). (See 'Decision to initiate antiretroviral therapy during early HIV infection' above.)
●The presence and severity of symptoms during early HIV infection appear to portend more rapid disease progression. Thus, those with acute symptomatic HIV infection may represent a subset of patients in whom earlier initiation of ART would be more likely to confer improvement in morbidity and mortality. (See 'Effect on symptomatic disease' above.)
●As in chronic infection, ART is effective in suppressing serum viral RNA levels and increasing CD4 cell counts in the vast majority of patients with acute and early HIV infection. Furthermore, initiation of ART earlier after initial HIV infection is associated with a greater chance of immune reconstitution to normal or near normal CD4 cell levels. (See 'Improved clinical markers of disease' above.)
●The interval following initial infection until the CD4 cell count declines to a threshold at which there is clinical evidence for a benefit with ART is relatively short. Thus, patients with early HIV who start therapy would likely not have a significant excess of ART exposure compared with deferring therapy. This may ameliorate concerns about the possible risk of additional toxicity from greater time on ART. (See 'Interval until treatment criteria are met is short' above and 'Potential risks' above.)
●Early HIV infection is associated with high levels of HIV RNA and a corresponding high risk of viral transmission. Reduction of this transmission risk through viral suppression is a theoretical but plausible benefit to earlier ART initiation. (See 'Decreased risk of transmission' above.)
●Overall, these potential benefits of earlier ART outweigh the potential risks of increased exposure to the toxicity of ART and emergence of viral resistance in the setting of suboptimal adherence. (See 'Our approach' above.)
•For patients with acute symptomatic HIV infection, we suggest initiation of ART (Grade 2C). Given the association between symptomatic disease and more rapid disease progression, these patients may be at greatest risk of delaying therapy and thus we feel strongly about treatment initiation in such patients.
•For patients with asymptomatic early HIV infection who are committed to lifelong therapy, we also suggest initiation of ART (Grade 2C).
•For those asymptomatic individuals who are not committed to taking therapy or who have significant barriers to adherence, a strategy of monitoring without HIV treatment is reasonable. We perform clinical evaluation, CD4 cell count, and viral load testing every three months for evidence of rapid immunologic decline, which would indicate a greater urgency for initiation of ART to prevent poor clinical outcomes. (See 'Patients who defer antiretroviral therapy' above.)
●The ultimate choice of antiretroviral regimen should be guided by the results of drug resistance testing, as transmission of virus harboring at least one resistance mutation is not uncommon. However, treatment does not have to be delayed while awaiting results of resistance testing. While awaiting results of resistance testing, we suggest an initial regimen that includes ritonavir-boosted darunavir (Grade 2C). Once initiated, ART is continued indefinitely. (See 'Selection of antiretroviral regimen' above and 'Duration of treatment' above and "Selecting antiretroviral regimens for the treatment-naïve HIV-infected patient".)
●Trials evaluating the effects of a discrete course of ART early in HIV infection suggest an improvement in surrogate markers of HIV disease with earlier versus delayed therapy, but the durability of these benefits following ART discontinuation is unclear. In contrast, substantial evidence from clinical trials in chronic infection demonstrate increased AIDS and non-AIDS related morbidity and mortality with treatment discontinuation. Thus, we recommend not using a treatment interruption strategy in patients with acute or early HIV infection (Grade 1A). (See 'Can ART in early infection alter disease course?' above.)
- Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 1:537.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on May 01, 2014).
- Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10.
- Kelley CF, Barbour JD, Hecht FM. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007; 45:445.
- Lavreys L, Baeten JM, Chohan V, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006; 42:1333.
- Kassutto S, Maghsoudi K, Johnston MN, et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006; 42:1024.
- Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med 2013; 368:218.
- Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717.
- HIV-CAUSAL Collaboration, Ray M, Logan R, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123.
- Sabine C, Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19:1995.
- Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815.
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.
- Minga AK, Lewden C, Gabillard D, et al. CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters. AIDS 2011; 25:819.
- Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis 2011; 53:817.
- Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis 2012; 205:87.
- Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.
- Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011; 364:1943.
- Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785.
- Xiridou M, Geskus R, de Wit J, et al. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS 2004; 18:1311.
- Abu-Raddad LJ, Longini IM Jr. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 2008; 22:1055.
- Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951.
- O'Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep 2012; 9:101.
- Volz EM, Ionides E, Romero-Severson EO, et al. HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med 2013; 10:e1001568; discussion e1001568.
- Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005; 191:1410.
- Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis 2007; 195:1762.
- Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013; 208:1202.
- Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART intervention restricts the seeding of the HIV reservoir in long-lived central memory CD4 T cells. Presented at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 47.
- Henrich TJ, Gandhi RT. Early treatment and HIV-1 reservoirs: a stitch in time? J Infect Dis 2013; 208:1189.
- Hey-Cunningham WJ, Murray JM, Natarajan V, et al. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. AIDS 2015; 29:911.
- Martínez-Bonet M, Puertas MC, Fortuny C, et al. Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy. Clin Infect Dis 2015; 61:1169.
- Ananworanich J, Chomont N, Eller LA, et al. HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine 2016; 11:68.
- Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523.
- Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A 2000; 97:3382.
- Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005; 19:1947.
- Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410.
- Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258.
- Jain V, Liegler T, Vittinghoff E, et al. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS One 2010; 5:e15510.
- Hurt CB, McCoy SI, Kuruc J, et al. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther 2009; 14:673.
- Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201:1063.
- Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014; 66:140.
- Chéret A, Nembot G, Mélard A, et al. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infect Dis 2015; 15:387.
- Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283.
- Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981.
- Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One 2012; 7:e43754.
- Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis 2014; 210:1529.
- Hatano H et al. Lack of detectable HIV DNA in a PrEP study participant treated during “hyperacute” HIV infection. Presented at the 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, March 3-6, 2014. Abstract #397LB
- Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013; 9:e1003211.
- Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828.
- Luzuriaga K, Gay H, Ziemniak C, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 2015; 372:786.
- Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med 2012; 9:e1001196.
- Fidler S and the SPARTAC Trials investigators. The effect of short-course antiretroviral therapy in primary HIV infection: final results from an international randomised controlled trial; SPARTAC. Presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention, Rome, Italy, July 17-20, 2011, #WELBX06
- Goujard C, Emilie D, Roussillon C, et al. Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial. AIDS 2012; 26:1895.
- Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23:1987.
- Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725.
- Seng R, Goujard C, Desquilbet L, et al. Rapid CD4+ cell decrease after transient cART initiated during primary HIV infection (ANRS PRIMO and SEROCO cohorts). J Acquir Immune Defic Syndr 2008; 49:251.
- Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS 2008; 22:2441.
- Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 2012; 172:1252.
- Hoen B, Fournier I, Lacabaratz C, et al. Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. J Acquir Immune Defic Syndr 2005; 40:307.
- SPARTAC Trial Investigators, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013; 368:207.